TITLE

Low doses of cholestyramine in the treatment of hyperthyroidism

AUTHOR(S)
Mahmoud Kaykhaei; Mesbah Shams; Abdosamad Sadegholvad; Mohammad Dabbaghmanesh; Gholamhossein Omrani
PUB. DATE
December 2008
SOURCE
Endocrine (1355008X);Dec2008, Vol. 34 Issue 1-3, p52
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Abstract  The enterohepatic circulation of thyroid hormones is increased in thyrotoxicosis. Bile-salt sequestrants bind thyroid hormones in the intestine and thereby increase their fecal excretion. Based on these observations, the use of cholestyramine has been tried. The present study evaluates the effect of low doses of cholestyramine as an adjunctive therapy in the management of hyperthyroidism. In a prospective, randomized, double-blind, placebo-controlled trial, 45 patients with newly diagnosed hyperthyroid Graves’ disease were randomly assigned into the following treatment protocols: group I, cholestyramine 2 g BID, methimazole and propranolol; group II, cholestyramine 1 g BID, methimazole and propranolol; group III, placebo powder, methimazole and propranolol. The fixed dose of methimazole (30 mg/d) and propranolol (40 mg/d) was used. The study period was 4 weeks. Serum total triiodothyronine and free thyroxin were measured at baseline, and at the ends of the second and the fourth week of the study. The serum thyroid hormone levels decreased more rapidly and to a greater extent in the cholestyramine-treated groups. All of the patients in group I had achieved euthyroid state at the end of the study. We conclude that low dose of cholestyramine is an effective and well-tolerated adjunctive agent in the treatment of hyperthyroid Graves’ disease. (ClinicalTrials.gov number, NCT00677469)
ACCESSION #
36232723

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics